Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.16.6463

The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals  

Tan, Heng Kean (Malaysian Institute of Pharmaceuticals and Nutraceuticals, Ministry of Science, Technology and Innovation (MOSTI))
Moad, Ahmed Ismail Hassan (Advanced Medical and Dental Institute, Universiti Sains Malaysia)
Tan, Mei Lan (Malaysian Institute of Pharmaceuticals and Nutraceuticals, Ministry of Science, Technology and Innovation (MOSTI))
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.16, 2014 , pp. 6463-6475 More about this Journal
Abstract
The mammalian target of rapamycin (mTOR) kinase plays an important role in regulating cell growth and cell cycle progression in response to cellular signals. It is a key regulator of cell proliferation and many upstream activators and downstream effectors of mTOR are known to be deregulated in various types of cancers. Since the mTOR signalling pathway is commonly activated in human cancers, many researchers are actively developing inhibitors that target key components in the pathway and some of these drugs are already on the market. Numerous preclinical investigations have also suggested that some herbs and natural phytochemicals, such as curcumin, resveratrol, timosaponin III, gallic acid, diosgenin, pomegranate, epigallocatechin gallate (EGCC), genistein and 3,3'-diindolylmethane inhibit the mTOR pathway either directly or indirectly. Some of these natural compounds are also in the clinical trial stage. In this review, the potential anti-cancer and chemopreventive activities and the current status of clinical trials of these phytochemicals are discussed.
Keywords
mTOR signalling pathway; PI3K/Akt/mTOR; natural compounds; mTOR inhibitors;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Ganley IG, Lam du H, Wang J, et al (2009). ULK1.ATG13. FIP200 complex mediates mTOR signalling and is essential for autophagy. J Biol Chem, 284, 12297-305.   DOI
2 Garcia-Echeverria C (2010). Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett, 20, 4308-12.   DOI   ScienceOn
3 Garikapaty VP, Ashok BT, Tadi K, et al (2006). 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun, 340, 718-25.   DOI
4 Gera JF, Mellinghoff IK, Shi Y, et al (2004). AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem, 279, 2737-46.   DOI
5 Gomez-Pinillos A, Ferrari AC (2012). mTOR signalling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am, 26, 483-505.   DOI
6 Guertin DA, Kim D-H, Sabatini DM (2004). Growth control through the mTOR network. In 'Cell Growth: Control of Cell Size' (Hall MN et al., eds), Cold Spring Harbor Laboratory Press, pp. 193-234.
7 Guertin DA, Sabatini DM (2009). The pharmacology of mTOR inhibition. Sci Signal, 2, 24.
8 Gullett NP, Ruhul Amin AR, Bayraktar S, et al (2010). Cancer prevention with natural compounds. Semin Oncol, 37, 258-81.   DOI   ScienceOn
9 Han D, Li SJ, Zhu YT, et al (2013). LKB1/AMPK/mTOR signalling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev, 14, 4033-9.   DOI
10 Kim ND, Mehta R, Yu W, et al (2002b). Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat, 71, 203-17.   DOI   ScienceOn
11 King FW, Fong S, Griffin C, et al (2009). Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. PloS one, 4, 7283.   DOI
12 Kirken RA, Wang YL (2003). Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc, 35, 227-30.   DOI
13 Kong D, Banerjee S, Huang W, et al (2008). Mammalian target of rapamycin repression by 3,3'-Diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor- D-overexpressing PC3 cells. Cancer Res, 68, 1927-34.   DOI   ScienceOn
14 Lao CD, Ruffin MTt, Normolle D, et al (2006). Dose escalation of a curcuminoid formulation. BMC Complement Altern Med, 6, 10.   DOI   ScienceOn
15 Laplante M, Sabatini DM (2012). mTOR signalling in growth control and disease. Cell, 149, 274-93.   DOI   ScienceOn
16 Laplante M, Sabatini DM (2013). Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci, 126, 1713-9.   DOI
17 Law BK (2005). Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol, 56, 47-60.   DOI   ScienceOn
18 Le HT, Schaldach CM, Firestone GL, et al (2003). Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem, 278, 21136-45.   DOI
19 Li JC, Zhu HY, Chen TX, et al (2013). Roles of mTOR and p-mTOR in gastrointestinal stromal tumors. Asian Pac J Cancer Prev, 14, 5925-8.   과학기술학회마을   DOI
20 Hardwick JS, Kuruvilla FG, Tong JK, et al (1999). Rapamycinmodulated transcription defines the subset of nutrientsensitive signalling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci USA, 96, 14866-70.   DOI   ScienceOn
21 Hasskarl J (2014). Everolimus. Recent Results Cancer Res, 201, 373-92.   DOI
22 Hay N, Sonenberg N (2004). Upstream and downstream of mTOR. Genes Dev, 18, 1926-45.   DOI   ScienceOn
23 He X, Wang Y, Zhu J, et al (2010). Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signalling. Cancer Lett, 28, 168-76
24 Lin JN, Lin VC, Rau KM, et al (2010). Resveratrol modulates tumor cell proliferation and protein translation via SIRT1- dependent AMPK activation. J Agric Food Chem, 58, 1584-92.   DOI   ScienceOn
25 Li M, Zhang Z, Hill DL, et al (2007). Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res, 67, 1988-96.   DOI   ScienceOn
26 Li Y, Sarkar FH (2002). Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signalling pathway. Clin Cancer Res, 8, 2369-77.
27 Li Y, Wang Z, Kong D, et al (2007). Regulation of FOXO3a/betacatenin/ GSK-3beta signalling by 3,3'-Diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem, 282, 21542-50.   DOI
28 Liu MJ, Wang Z, Ju Y, et al (2005). Diosgenin induces cell cycle arrest and apoptosis in human leukemia K562 cells with the disruption of Ca2+ homeostasis. Cancer Chemother Pharmacol, 55, 79-90.   DOI   ScienceOn
29 Liu P, Cheng H, Roberts TM, et al (2009a). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov, 8, 627-44.   DOI   ScienceOn
30 Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS (2009b). mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg, 6, 47-55.   DOI
31 Loewith R, Jacinto E, Wullschleger S, et al (2002). Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell, 10, 457-68.   DOI   ScienceOn
32 LoPiccolo J, Blumenthal GM, Bernstein WB, et al (2008). Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat, 11, 32-50.   DOI   ScienceOn
33 Messing E, Gee JR, Saltzstein DR, et al (2012). A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res, 5, 621-30.   DOI
34 Malik A, Afaq F, Sarfaraz S, et al (2005). Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA, 102, 14813-8.   DOI   ScienceOn
35 Manning BD, Cantley LC (2007). AKT/PKB signalling: navigating downstream. Cell, 129, 1261-74.   DOI   ScienceOn
36 Marques FZ, Markus MA, Morris BJ (2009). Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol, 41, 2125-8.   DOI   ScienceOn
37 Mita MM, Mita A, Rowinsky EK (2003). The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther, 2, 169-77.
38 Moalic S, Liagre B, Corbiere C, et al (2001). A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. FEBS Lett, 506, 225-30.   DOI   ScienceOn
39 Moschetta M, Reale A, Marasco C, et al (2014). Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol, [Epub ahead of print]
40 Nagle DG, Ferreira D, Zhou YD (2006). Epigallocatechin-3- gallate (EGCG): chemical and biomedical perspectives. Phytochemistry, 67, 1849-55.   DOI   ScienceOn
41 Nakamura Y, Yogosawa S, Izutani Y, et al (2009). A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer, 8, 100.   DOI
42 O'Reilly KE, Rojo F, She QB, et al (2006). mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res, 66, 1500-8.   DOI   ScienceOn
43 Nave BT, Ouwens M, Withers DJ, et al (1999). Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J, 344, 427-31.   DOI   ScienceOn
44 Nicholson KM, Anderson NG (2002). The protein kinase B/ Akt signalling pathway in human malignancy. Cell Signal 14, 381-95.   DOI   ScienceOn
45 Noh WC, Mondesire WH, Peng J, et al (2004). Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res, 10, 1013-23.   DOI   ScienceOn
46 Pal I, Mandal M (2012). PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin, 33, 1441-58.   DOI
47 Paller CJ, Ye X, Wozniak PJ, et al (2013). A randomized Phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis, 16, 50-5.   DOI
48 Pandurangan AK (2013). Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pac J Cancer Prev, 14, 2201-5.   과학기술학회마을   DOI   ScienceOn
49 Pantuck AJ, Leppert JT, Zomorodian N, et al (2006). Phase II study of pomegranate juice for men with rising prostatespecific antigen following surgery or radiation for prostate cancer. Clin Cancer Res, 12, 4018-26.   DOI   ScienceOn
50 Pervaiz S (2003). Resveratrol: from grapevines to mammalian biology. FASEB J, 17, 1975-85.   DOI   ScienceOn
51 Popat R, Plesner T, Davies F, et al (2013). A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol 160, 714-7.   DOI
52 Peterson TR, Laplante M, Thoreen CC, et al (2009). DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 137, 873-86.   DOI   ScienceOn
53 Philips BJ, Coyle CH, Morrisroe SN, et al (2009). Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res, 30, 207-15.   DOI
54 Plas DR, Thompson CB (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene, 24, 7435-42.   DOI   ScienceOn
55 Porta C, Paglino C, Mosca A (2014). Targeting PI3K/Akt/mTOR signalling in cancer. Fron Oncol, 4, 64.
56 Powers T, Walter P (1999). Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signalling pathway in Saccharomyces cerevisiae. Mol Biol Cell, 10, 987-1000.   DOI
57 Proud CG (2002). Regulation of mammalian translation factors by nutrients. Eur J Biochem, 269, 5338-49.   DOI   ScienceOn
58 Pyrko P, Schonthal AH, Hofman FM, et al (2007). The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res, 67, 9809-16.   DOI   ScienceOn
59 Qiao Y, Cao J, Xie L, et al (2009). Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch Pharm Res, 32, 1309-15.   DOI
60 Ravindranath MH, Muthugounder S, Presser N, et al (2004). Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol, 546, 121-65.   DOI
61 Sabers CJ, Martin MM, Brunn GJ, et al (1995). Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem, 270, 815-22.   DOI   ScienceOn
62 Rodon J, Dienstmann R, Serra V, et al (2013). Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol, 10, 143-53.   DOI
63 Ryan JL, Heckler CE, Ling M, et al (2013). Curcumin for radiation dermatitis: a randomized, double-blind, placebocontrolled clinical trial of thirty breast cancer patients. Radiat Res, 180, 34-43.   DOI
64 Sabatini DM, Erdjument-Bromage H, Lui M, et al (1994). RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell, 78, 35-43.   DOI   ScienceOn
65 Sakamoto T, Horiguchi H, Oguma E, et al (2010). Effects of diverse dietary phytoestrogens on cell growth, cell cycle and apoptosis in estrogen-receptor-positive breast cancer cells. J Nutr Biochem, 21, 856-64.   DOI
66 Sancak Y, Thoreen CC, Peterson TR, et al (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell, 25, 903-15.
67 Sansal I, Sellers WR (2004). The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol, 22, 2954-63.   DOI
68 Sarbassov DD, Ali SM, Kim DH, et al (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol, 14, 1296-302.   DOI   ScienceOn
69 Sarbassov DD, Ali SM, Sengupta S, et al (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/ PKB. Mol Cell, 22, 159-68.   DOI   ScienceOn
70 Sehgal SN, Baker H, Vezina C (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo), 28, 727-32.   DOI
71 Seo BR, Min KJ, Cho IJ, et al (2014). Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235- induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PloS one, 9, 95588.   DOI
72 Sharma RA, McLelland HR, Hill KA, et al (2001). Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res, 7, 1894-900.
73 Sharp Z, Richardson A (2011). Aging and cancer: can mTOR inhibitors kill two birds with one drug? Target Oncol, 6, 41-51.   DOI
74 Shimobayashi M, Hall MN (2014). Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol, 15, 155-62.   DOI
75 Shishodia S, Chaturvedi MM, Aggarwal BB (2007). Role of curcumin in cancer therapy. Curr Probl Cance, 31, 243-305.   DOI
76 Shor B, Gibbons JJ, Abraham RT, et al (2009). Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 8, 3831-7.   DOI
77 Soliman GA, Acosta-Jaquez HA, Dunlop EA, et al (2010). mTOR Ser-2481 autophosphorylation monitors mTORCspecific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem, 285, 7866-79.   DOI
78 Srinivasan S, Koduru S, Kumar R, et al (2009). Diosgenin targets Akt-mediated prosurvival signalling in human breast cancer cells. Int J Cancer, 125, 961-7.   DOI
79 Sun SY, Rosenberg LM, Wang X, et al (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res, 65, 7052-8.   DOI
80 Sun J, Chu Y-F, Wu X, et al (2002). Antioxidant and antiproliferative activities of common fruits. J Agric Food Chem, 50, 7449-54.   DOI   ScienceOn
81 Sy LK, Yan SC, Lok CN, et al (2008). Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res, 68, 10229-37.   DOI   ScienceOn
82 Tabernero J, Rojo F, Calvo E, et al (2008). Dose- and scheduledependent inhibition of the mammalian target of rapamycin pathway with everolimus: a Phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26, 1603-10.   DOI
83 Takahashi Y, Kohashi K, Yamada Y, et al (2014). Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas. Human pathol, 45, 984-93.   DOI
84 Tang KD, Ling MT (2014). Targeting Drug-Resistant Prostate Cancer with Dual PI3K/MTOR Inhibition. Curr Med Chem, [Epub ahead of print].
85 Tokunaga E, Oki E, Egashira A, et al (2008). Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets, 8, 27-36.   DOI   ScienceOn
86 Tsang CK, Qi H, Liu LF, et al (2007). Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today, 12, 112-24.   DOI   ScienceOn
87 Vakana E, Sassano A, Platanias LC (2010). Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCRABL- expressing leukemic cells. Autophagy, 6, 966-7.   DOI
88 Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer, 2, 489-501.   DOI   ScienceOn
89 Wan X, Harkavy B, Shen N, et al (2007). Rapamycin induces feedback activation of Akt signalling through an IGF-1Rdependent mechanism. Oncogene, 26, 1932-40.   DOI
90 Vogt PK, Hart JR, Gymnopoulos M, et al (2010). Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol, 347, 79-104.
91 Wang XW, Zhang YJ (2014). Targeting mTOR network in colorectal cancer therapy. World J Gastroenterol, 20, 4178-88.   DOI
92 Wu Y, Kim J, Elshimali Y, et al (2014). Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice. BMC Cancer, 14, 266.   DOI
93 Yap TA, Garrett MD, Walton MI, et al (2008). Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol, 8, 393-412.   DOI   ScienceOn
94 Yu K, Toral-Barza L, Discafani C, et al (2001). mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer, 8, 249-58.   DOI
95 Zhang J, Meng Z, Zhang M, et al (1999). Effect of six steroidal saponins isolated from anemarrhenae rhizoma on platelet aggregation and hemolysis in human blood. Clin Chim Acta, 289, 79-88.   DOI   ScienceOn
96 Zhang Q, Kelly AP, Wang L, et al (2006). Green tea extract and (-)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/AkT signalling pathways. J Invest Dermatol, 126, 2607-13.   DOI   ScienceOn
97 Zhao JJ, Cheng H, Jia S, et al (2006). The $p110{\alpha}$ isoform of PI3K is essential for proper growth factor signalling and oncogenic transformation. Proc Natl Acad Sci USA, 103, 16296-300.   DOI
98 Aggarwal BB, Bhardwaj A, Aggarwal RS, et al (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res, 24, 2783-840.
99 Abdulkareem IH, Blair M (2013). Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J, 54, 79-86.   DOI
100 Abraham RT (1998). Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signalling. Curr Opin Immunol, 10, 330-6.   DOI
101 Anastasius N, Boston S, Lacey M, Storing N, Whitehead SA (2009). Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway. J Steroid Biochem Mol Biol, 116, 50-5.   DOI
102 Aoki H, Takada Y, Kondo S, et al (2007). Evidence that curcumin suppresses the growth of malignant gliomas In vitro and In vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signalling pathways. Mol Pharmacol, 72, 29-39.   DOI   ScienceOn
103 Baselga J (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 16, 12-9.
104 Aziz MH, Nihal M, Fu VX, et al (2006). Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/ Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 5, 1335-41.   DOI   ScienceOn
105 Ballou LM, Lin RZ (2008). Rapamycin and mTOR kinase inhibitors. J Chem Biol, 1, 27-36.   DOI   ScienceOn
106 Banerjee S, Zhang Y, Wang Z, et al (2007). In vitro and In vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer, 120, 906-17.   DOI
107 Beevers CS, Chen L, Liu L, et al (2009). Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res, 69, 1000-8.   DOI   ScienceOn
108 Beevers CS, Li F, Liu L, et al (2006). Curcumin inhibits the mammalian target of rapamycin-mediated signalling pathways in cancer cells. Int J Cancer, 119, 757-64.   DOI   ScienceOn
109 Bharti AC, Aggarwal BB (2002). Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol, 64, 883-8.   DOI   ScienceOn
110 Brito PM, Devillard R, Negre-Salvayre A, et al (2009). Resveratrol inhibits the mTOR mitogenic signalling evoked by oxidized LDL in smooth muscle cells. Atherosclerosis 205, 126-34.   DOI   ScienceOn
111 Brown VA, Patel KR, Viskaduraki M, et al (2010). Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res, 70, 9003-11.   DOI
112 Hosokawa N, Sasaki T, Iemura S, et al (2009). Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy, 5, 973-9.   DOI
113 He Y, Li D, Cook SL, et al (2013). Mammalian target of rapamycin and Rictor control neutrophil chemotaxis by regulating Rac/Cdc42 activity and the actin cytoskeleton. Mol Biol Cell, 24, 3369-80.   DOI
114 Heath EI, Heilbrun LK, Li J, et al (2010). A Phase I doseescalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am J Transl Res, 2, 402-11.
115 Hidalgo M, Rowinsky EK (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6.   DOI   ScienceOn
116 Houghton PJ (2010). mTOR and Cancer Therapy: General Principles (V. A. Polunovsky and P. J. Houghton, Ed.^ Eds.), pp. 113-31. Humana Press, Springer New York Dordrecht Heidelberg London.
117 Chen HX, Sharon E (2013). IGF-1R as an anti-cancer target-- trials and tribulations. Chin J Cancer, 32, 242-52.   DOI
118 Caron E, Ghosh S, Matsuoka Y, et al (2010). A comprehensive map of the mTOR signalling network. Mol Syst Biol, 6, 453.
119 Carroll RE, Benya RV, Turgeon DK, et al (2011). Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res, 4, 354-64.   DOI
120 Chan S (2004). Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91, 1420-4.   DOI   ScienceOn
121 Cheng AL, Hsu CH, Lin JK, et al (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with highrisk or pre-malignant lesions. Anticancer Res, 21, 2895-900.
122 Chiang CT, Way TD, Tsai SJ, et al (2007). Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett, 581, 5735-42.   DOI   ScienceOn
123 Chow HH, Garland LL, Hsu CH, et al (2010). Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res, 3, 1168-75.   DOI   ScienceOn
124 Chu Y-F, Sun J, Wu X, et al (2002). Antioxidant and antiproliferative activities of common vegetables. J Agr Food Chem, 50, 6910-6.   DOI   ScienceOn
125 Cragg GM, Newman DJ, Snader KM (1997). Natural products in drug discovery and development. J Nat Prod, 60, 52-60.   DOI   ScienceOn
126 da Rocha AB, Lopes RM, Schwartsmann G (2001). Natural products in anticancer therapy. Curr Opin Pharmacol, 1, 364-9.   DOI   ScienceOn
127 Huang S, Houghton PJ (2003). Targeting mTOR signalling for cancer therapy. Curr Opin Pharmacol, 3, 371-7.   DOI   ScienceOn
128 Howells LM, Berry DP, Elliott PJ, et al (2011). Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-- safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res, 4, 1419-25.   DOI
129 Hsieh TC, Wu JM (2009). Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res, 29, 4025-32.
130 Huang CH, Tsai SJ, Wang YJ, et al (2009). EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol Nutr Food Res, 53, 1156-65.   DOI   ScienceOn
131 Hwang YW, Kim SY, Jee SH, et al (2009). Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer, 61, 598-606.   DOI
132 Inoki K, Li Y, Zhu T, et al (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol, 4, 648-57.   DOI   ScienceOn
133 Irving GR, Howells LM, Sale S, et al (2013). Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability. Cancer Prev Res (Phila), 6, 119-28.   DOI
134 Jacinto E, Loewith R, Schmidt A, et al (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol, 6, 1122-8.   DOI   ScienceOn
135 Jiang H, Shang X, Wu H, et al (2009). Resveratrol downregulates PI3K/Akt/mTOR signalling pathways in human U251 glioma cells. J Exp Ther Oncol, 8, 25-33.
136 Dowling RJ, Topisirovic I, Fonseca BD, et al (2010). Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta, 1804, 433-9.   DOI
137 Dalessandri KM, Firestone GL, Fitch MD, et al (2004). Pilot study: effect of 3,3'-Diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer, 50, 161-7.   DOI
138 Das A, Banik NL, Ray SK (2010). Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer, 116, 164-76.
139 Dhillon N, Aggarwal BB, Newman RA, et al (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res, 14, 4491-9.   DOI   ScienceOn
140 Faria A, Calhau C (2010). Chapter 36 - Pomegranate in human health: an overview (W. Ronald Ross and R. P. Victor, Ed.^ Eds). Academic Press, San Diego, pp. 551-63.
141 Faried A, Kurnia D, Faried LS, et al (2007). Anticancer effects of gallic acid isolated from Indonesian herbal medicine, Phaleria macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int J Oncol, 30, 605-13.
142 Fingar DC, Richardson CJ, Tee AR, et al (2004). mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol, 24, 200-16.   DOI
143 Fruman DA, Rommel C (2014). PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov, 13, 140-56.   DOI
144 Galluzzi L, Vicencio JM, Kepp O, et al (2008). To die or not to die: that is the autophagic question. Curr Mol Med, 8, 78-91.   DOI   ScienceOn
145 Kanai M, Yoshimura K, Asada M, et al (2011). A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol, 68, 157-64.   DOI
146 Johnson SM, Gulhati P, Arrieta I, et al (2009). Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/ mTOR signalling. Anticancer Res, 29, 3185-90.
147 Jung CH, Jun CB, Ro SH, et al (2009). ULK-Atg13-FIP200 complexes mediate mTOR signalling to the autophagy machinery. Mol Biol Cell, 20, 1992-2003.   DOI   ScienceOn
148 Kanai M, Otsuka Y, Otsuka K, et al (2013). A Phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol, 71, 1521-30.   DOI
149 Kang Y-J, Chung H-J, Nam J-W, et al (2011). Cytotoxic and antineoplastic activity of timosaponin a-iii for human colon cancer cells. J Nat Prod, 74, 701-6.   DOI
150 Katiyar S, Elmets CA, Katiyar SK (2007). Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair. J Nutr Biochem, 18, 287-96.   DOI   ScienceOn
151 Khan N, Afaq F, Kweon MH, et al (2007a). Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res, 67, 3475-82.   DOI   ScienceOn
152 Khan N, Hadi N, Afaq F, et al (2007b). Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis, 28, 163-73.   DOI   ScienceOn
153 Kim DH, Sarbassov DD, Ali SM, et al (2002a). mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 110, 163-75.   DOI   ScienceOn
154 Kim SH, Kim YB, Jeon YT, et al (2009). Genistein inhibits cell growth by modulating various mitogen-activated protein kinases and AKT in cervical cancer cells. Ann NY Acad Sci, 1171, 495-500.   DOI   ScienceOn
155 Asnaghi L, Bruno P, Priulla M, et al (2004). mTOR: a protein kinase switching between life and death. Pharmacol Res 50, 545-9.   DOI   ScienceOn
156 Ghayad SE, Cohen PA (2010). Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat Anticancer Drug Discov, 5, 29-57.   DOI
157 Kadowaki M, Kanazawa T (2003). Amino acids as regulators of proteolysis. J Nutr, 133, 2052-6.
158 Vezina C, Kudelski A, Sehgal SN (1975). Rapamycin (AY- 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot, 28, 721-6.   DOI